Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.67 |
| ▸ | MMP2 | P08253 | 3/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 11/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.49 |
| ▸ | RECQL | P46063 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | USP2 | O75604 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HBB | P68871 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 9/20 | 0.45 |
| ▸ | THRB | P10828 | 9/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | S100A4 | P26447 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504362 | 0.93 | PTGS1 (0.56) | PTGS1MMP2HTR2BFNTAFNTB | |
| Rodorubicin SCHEMBL29352818 | 0.92 | MEN1 (0.58) | PTGS1MMP2HTR2BFNTAFNTB | |
| Rodorubicin SCHEMBL8693 | 0.92 | MEN1 (0.58) | PTGS1MMP2HTR2BFNTAFNTB | |
| SCHEMBL29403905 | 0.92 | PTGS1 (0.54) | PTGS1MMP2HTR2BFNTAFNTB | |
| SCHEMBL29356967 | 0.89 | PTGS1 (0.57) | PTGS1MMP2HTR2BFNTAFNTB | |
| SCHEMBL29557045 | 0.87 | MMP2 (0.58) | PTGS1MMP2HTR2BFNTAFNTB | |
| SCHEMBL29381144 | 0.87 | PTGS1 (0.50) | PTGS1MMP2HTR2BFNTAFNTB | |
| SCHEMBL29467023 | 0.87 | PTGS1 (0.77) | PTGS1MMP2HTR2BFNTAFNTB | |
| SCHEMBL30864532 | 0.85 | PTGS1 (0.65) | PTGS1MMP2HTR2BFNTAFNTB | |
| SCHEMBL31237728 | 0.84 | PTGS1 (0.88) | PTGS1MMP2HTR2BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-03 | — | — | US | claimed |
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-03 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | DNMT1, DNMT3B, DNMT3A | PTGS1 4202/4885MMP2 2017/4885HTR2B 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.